Discover open access scientific publications

Search, annotate, share and cite publications

Publications by K. Park

P2.01-33 Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-Pd-(L)1 Containing Therapy (HUDSON)

Journal of Thoracic Oncology

English

P1.01-21 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control in ATLANTIC

Journal of Thoracic Oncology

English

OA 05.03 Clinical Activity of ASP8273 in Asian Non-Small Cell Lung Cancer Patients With EGFR Activating and T790M Mutations

Journal of Thoracic Oncology

English

P1.04-03 Suppressive Immune Cell Profiling in Patients With Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

P1.01-11 Named Patient Use Program for Afatinib in Advanced NSCLC With Progression on Prior Therapy: Experience From Asian Centers

Journal of Thoracic Oncology

English

OA10.06 a First-In-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology

English

P3.01-082 Surgical Rebiopsy in Advanced Non-Small Cell Lung Cancer Resistant to Previous Chemotherapy

Journal of Thoracic Oncology

English

Cervical Conization and Sentinel Lymph Node Mapping in the Treatment of Stage I Cervical Cancer: Is Less Enough?

English

Effect of Synthesis Method on Photoluminescence Properties of Na2Sr2Al2PO4Cl9:Ce3+ Nanophosphor

Nano-Micro Letters

Surfaces

Electronic Engineering

English

An Endoplasmic Reticulum Stress-Initiated Sphingolipid Metabolite, Ceramide-1-Phosphate, Regulates Epithelial Innate Immunity by Stimulating -Defensin Production

Molecular and Cellular Biology

Cell Biology

Molecular Biology

2014

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by K. Park

P2.01-33 Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-Pd-(L)1 Containing Therapy (HUDSON)

P1.01-21 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control in ATLANTIC

OA 05.03 Clinical Activity of ASP8273 in Asian Non-Small Cell Lung Cancer Patients With EGFR Activating and T790M Mutations

P1.04-03 Suppressive Immune Cell Profiling in Patients With Non-Small Cell Lung Cancer

P1.01-11 Named Patient Use Program for Afatinib in Advanced NSCLC With Progression on Prior Therapy: Experience From Asian Centers

OA10.06 a First-In-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

P3.01-082 Surgical Rebiopsy in Advanced Non-Small Cell Lung Cancer Resistant to Previous Chemotherapy

Cervical Conization and Sentinel Lymph Node Mapping in the Treatment of Stage I Cervical Cancer: Is Less Enough?

Effect of Synthesis Method on Photoluminescence Properties of Na2Sr2Al2PO4Cl9:Ce3+ Nanophosphor

An Endoplasmic Reticulum Stress-Initiated Sphingolipid Metabolite, Ceramide-1-Phosphate, Regulates Epithelial Innate Immunity by Stimulating -Defensin Production